Global

Investors

Financial Calendar 2015
11 Feb - Half Year Results
12 Aug - Full Year Results
15 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Mark Dehring
Mark Dehring
Head of Investor Relations
Phone: +613 9389 2818
mark.dehring@csl.com.au
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

CSL Share Price

Visit our CSL Share Price page to access the quote table and price chart.

About CSL

CSL Limited has over 13,000 staff in more than 27 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.

ASX Releases

23/04/2015
Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012. More.

30/03/2015
European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). More.

11/02/2015
Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%. More.

Prior ASX Releases

>> View the ASX Archive


Share
LinkedIn Twitter Facebook Google+